Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities.
Bruno Pedraz-Petrozzi, Michael Deuschle, Maria Gilles
Clinical Case Reports March 1, 2023 DOI: 10.1002/ccr3.7045 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | 42-year-old patient with severe treatment-resistant depression and psychiatric comorbidities |
| Intervention | Dextromethorphan/bupropion |
| Topics | Depression |
| Keywords | Bupropion Comorbidity Dextromethorphan Suicidal ideation |
| Key findings | Dextromethorphan/bupropion was associated with improved mood and reduced suicide risk in a patient with treatment-resistant depression. |
Abstract
We admitted a 42-year-old patient with severe treatment-resistant depression and with psychiatric comorbidities. The patient attempted suicide 5 weeks after admission. Subsequently, we initiated dextromethorphan/bupropion based on prior evidence. As a result, the patient demonstrated an improvement in mood symptoms and a reduction in suicide risk, leading to her discharge.
Comparable studies
Other case reports and case series on depression, most cited first.
Citations in the library
Cited by 2
- Oral Glutamatergic Augmentation for Trauma-Related Disorders with Fluoxetine- / Bupropion- Potentiated Dextromethorphan ± Piracetam: A Four-Patient Case Series Research Square November 25, 2025
- Case Report: Oral glutamatergic augmentation for trauma-related disorders with fluoxetine-/bupropion-potentiated dextromethorphan ± piracetam: a four-patient case series. Frontiers in Psychiatry 2026
Cites 7
- Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood. Psychopharmacology Bulletin April 8, 2025
- Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials Expert Opinion on Emerging Drugs January 2, 2021
- Dextromethorphan/Bupropion: First Approval CNS Drugs October 27, 2022
- Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). The Journal of Clinical Psychiatry May 30, 2022
- Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. American Journal of Psychiatry May 18, 2022
and 2 more in the library